We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
-21.98%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
$0
(0%)
Cap. Flow
-$63.6K
Cap. Flow
% of AUM
-0%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,173
New
–
Increased
3
Reduced
4
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IDXG
Interpace Biosciences, Inc. Common Stock
IDXG
|
+$51.9K |
| 2 |
Ovintiv
OVV
|
+$14.7K |
| 3 |
Vivani Medical
VANI
|
+$119 |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Brookfield Infrastructure Partners
BIP
|
+$78.8K |
| 2 |
Telus
TU
|
+$37K |
| 3 |
Old Dominion Freight Line
ODFL
|
+$14.5K |
| 4 |
BBBY
Bed Bath & Beyond
BBBY
|
+$11 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q1 2020 Portfolio in Review
As of Q1 2020, Glenmede Trust held 3,173 positions worth $21.9B, unchanged from the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Trading was light in Q1 2020: portfolio turnover was 0%. Glenmede Trust opened no new positions and made no exits, leaving the 3,173-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 19% of assets, unchanged from a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust added most to Interpace Biosciences, Inc. Common Stock in Q1 2020, an estimated $51.9K increase.
- Glenmede Trust's biggest Q1 2020 reduction was Brookfield Infrastructure Partners, cutting an estimated $78.8K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q1 2020.
- Glenmede Trust opened 0 new positions and closed 0 in Q1 2020.
- Glenmede Trust's portfolio value was unchanged quarter-over-quarter at $21.9B.
Based on Glenmede Trust's 13F filing for Q1 2020, filed 20 May 2020.